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Abstract
Background: Parkin (PARK2) is an E3 ubiquitin ligase that is commonly mutated in Familial Parkinson’s Disease (PD).
In cell culture models, Parkin is recruited to acutely depolarised mitochondria by PINK1. PINK1 activates Parkin
activity leading to ubiquitination of multiple proteins, which in turn promotes clearance of mitochondria by
mitophagy. Many substrates have been identified using cell culture models in combination with depolarising drugs
or proteasome inhibitors, but not in more physiological settings.
Methods: Here we utilized the recently introduced BioUb strategy to isolate ubiquitinated proteins in flies.
Following Parkin Wild-Type (WT) and Parkin Ligase dead (LD) expression we analysed by mass spectrometry and
stringent bioinformatics analysis those proteins differentially ubiquitinated to provide the first survey of steady state
Parkin substrates using an in vivo model. We further used an in vivo ubiquitination assay to validate one of those
substrates in SH-SY5Y cells.
Results: We identified 35 proteins that are more prominently ubiquitinated following Parkin over-expression.
These include several mitochondrial proteins and a number of endosomal trafficking regulators such as v-ATPase
sub-units, Syx5/STX5, ALiX/PDCD6IP and Vps4. We also identified the retromer component, Vps35, another
PD-associated gene that has recently been shown to interact genetically with parkin. Importantly, we validated
Parkin-dependent ubiquitination of VPS35 in human neuroblastoma cells.
Conclusions: Collectively our results provide new leads to the possible physiological functions of Parkin activity
that are not overtly biased by acute mitochondrial depolarisation.
Keywords: Parkin (PARK2), Parkin substrates, Ubiquitination, VPS35, Neurodegeneration, In vivo, Drosophila
melanogaster, Parkinson’s Disease (PD), Alzheimer’s Disease (AD), Label Free Quantification (LFQ)
Background
Parkinson’s Disease (PD) is the most common form of
Parkinsonism and the second most common neurode-
generative disease after Alzheimer’s. PD patients display
resting tremor, rigidity and postural disability, usually ac-
companied by other non-motor symptoms. Phenotypic-
ally, PD is mainly characterized by loss of dopaminergic
neurons in the substantia nigra and the presence of
Lewy bodies [1, 2]. PD has been classically considered a
sporadic disease linked to aging with an unknown
aetiology. However, in about 10% of the cases, mutations
in specific genes cause Familial forms of PD. These genes
show Mendelian inheritance and can be classified as either
autosomal dominant (SNCA, LRRK2, VPS35) or auto-
somal recessive (PARK2, PARK7, PINK1, ATP13A2,
FBXO7, PLA2G6, DNAJC6, SYNJ1). Moreover, recent ex-
ome sequencing and cohort genome-wide association
studies (GWAS) have identified several other risk factor
genes associated with sporadic PD and other Parkinsonian
syndromes [3–6]. The set of genes implicated in PD en-
code for proteins involved in mitochondrial homeostasis,
autophagy, endo-lysosomal trafficking, Ca+2 homeostasis
and dopamine homeostasis [7–10]. However, the exact
pathophysiological mechanisms leading to the disease are
not yet clear. At the moment there is no effective
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biomarker for the diagnosis of PD, which can only be de-
termined by postmortem brain analysis [11].
Amongst PD related genes, mutations in Parkin
(PARK2) and PTEN-induced kinase 1 (PINK1) cause
early-onset Familial PD [12, 13]. Parkin is a RING be-
tween RING (RBR) E3 ubiquitin ligase, which conveys
the transfer of ubiquitin onto selected substrate proteins
[14, 15]. Parkin null Drosophila melanogaster display
Parkinsonian-like phenotypes including reduced life
span, climbing and flying disability, sterility, mitochon-
drial defects and dopaminergic neurodegeneration [16].
Genetic studies in Drosophila established that pink1 acts
upstream of parkin to maintain mitochondrial integrity
[17, 18]. Upon mitochondrial depolarization PINK1 ac-
cumulates at the Outer Mitochondrial Membrane
(OMM), where it phosphorylates both ubiquitin and the
Ubiquitin-like (UBL) domain of Parkin to recruit and
activate latent Parkin ubiquitin ligase activity [19–25].
Activated Parkin ubiquitinates several OMM proteins
and promotes both proteasome-dependent degradation
of specific proteins and mitophagy, a specialised type of
autophagy where the whole mitochondrion is engulfed
into autophagosomes [26–28].
PINK1 and Parkin are widely considered neuroprotec-
tive and different studies have shown that PINK1/Parkin
over-expression can protect against cell death in a num-
ber of contexts in vitro and in vivo [29]. Therefore it has
been proposed that drugs promoting PINK1/Parkin -
dependent mitophagy could serve as effective treatments
for PD. However, recent evidence demonstrates that ex-
cessive Parkin over-expression results in sensitization to
cell death using in vitro [30–32] and in vivo models [33].
It is essential to identify physiologically relevant Parkin
substrates to understand the pathways leading to PD in
order to develop a treatment. A considerable number of
proteins have been reported to be Parkin substrates but
most of the work has relied on cultured cells, mainly of
epithelial origin, usually upon treatment with mitochon-
drial depolarising agents [27, 34–38]. Here we extend this
approach by performing a high throughput mass spec-
trometry proteomic study of Parkin substrates in vivo. We
have utilised a fly model expressing constitutively biotinyl-
ated ubiquitin [39–43] to purify proteins ubiquitinated by
Parkin in Drosophila neurons. Our study identifies both
established and novel Parkin substrates.
Methods
DNA construction
Drosophila park gene was amplified from a Drosophila
cDNA library (DGC realease 1.0, Berkeley Drosophila
Genome Project) and FLAG-tag cloned at its 5’-end
using the FLAG-parkin-Fw (GCCCTCGAGATGGATT
ACAAGGATGATGACGATAAGATGAGTTTTATTTTT
AAATTTATTGCCAC) and parkin-Rv (GCCTCTAGATT
AGCCGAACCAGTGGGCTCC) primers. This construct
was then inserted into a pUASattb vector between the
XhoI and XbaI sites. Ligase-dead FLAG-Parkin (ParkinLD)
was generated by mutating the C449 to S using the
QuikChange Site-Directed Mutagenesis Kit (Stratagene)
according to manufacturer’s instructions. The primers
used for mutagenesis were C449S-Fw (GGAGCGAG
ATGGCGGTAGCATGCACATGGTCTGCACACG) and
C449S-Rv (CGTGTGCAGACCATGTGCATGCTACCG
CCATCTCGCTCC). Untagged human Parkin and Parkin
(C431S) were amplified from pcDNA3.1(+)-HA-Parkin
and pcDNA3.1(+)-HA-Parkin(C431S) respectively with
primers forward (GCCGAAGCTTAACCATGATAGTGT
TTGTCAGG) and reverse (AGTCTAGACTACACGTCG
AACCAGTGGTCCTGGG). PCR products were inserted
into pcDNA3.1(+) between HindIII and XbaI.
Antibodies
The following antibodies were used against Drosophila
proteins: goat anti-biotin-horseradish peroxidase (HRP)
conjugated antibody (Cell Signalling); chicken polyclonal
anti-BirA antibody (Sigma); rabbit polyclonal anti-Parkin
antibody [44]; mouse monoclonal anti-Syx1A antibody
(DSHB); rabbit polyclonal anti-RdhB [45]; rabbit poly-
clonal anti-ArgK [46]; rabbit polyclonal anti-Vps4 [47];
rabbit polyclonal anti-Fax antibody (a gift from Eric
Liebl); rabbit polyclonal anti-Ubiquitin antibody (Sigma).
The following antibodies were used against Human pro-
teins: goat polyclonal anti-VPS35 antibody (Abcam);
mouse monoclonal anti-Cleaved Parp-85 fragment (Cell
Signaling); mouse monoclonal anti-Parkin (Santa Cruz);
rabbit polyclonal anti-PINK1 (Novus Biologicals); rabbit
polyclonal anti-Miro1 (Sigma); rabbit polyclonal anti-
Tim44 (Sigma); rabbit polyclonal anti-Tom20 (Sigma);
mouse monoclonal (Abcam) and rabbit polyclonal
(Sigma) anti-Actin. For monitoring the GFP pull-downs
the following antibodies were used: monoclonal mouse
anti-GFP antibody (Roche) and monoclonal mouse anti-
Flag M2-HRP conjugated antibody (Sigma). Anti-mouse,
rabbit and chicken HRP labelled secondary antibodies
(Jackson ImmunoResearch Laboratories) and anti-guinea
pig (Invitrogen) were used; and anti-mouse, rabbit and
sheep IR 680 and IR800-coupled antibodies (LI-COR
Biosciences).
Drosophila stocks
UAS-BirA and UAS-(BioUb)6-BirA [39] and their recom-
bination with GMR-GAL4 flies for the study of ubiquitin
proteomics has been previously described [43]. FLAG-
tagged Parkin wild-type (ParkinWT) and ParkinLD flies
were generated at Bestgene using the pUASattb constructs
described above. Both UAS-ParkinWT and UAS-ParkinLD
lines were independently crossed with GMR-GAL4,UAS-
(BioUb)6-BirA to finally generate: GMR-GAL4,UAS-
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(BioUb)6-BirA/CyO;UAS-Parkin
WT and GMR-GAL4,UAS-
(BioUb)6-BirA/CyO;UAS-Parkin
LD. GMR-GAL4/CyO;UAS-
BirA/TM6 and GMR-GAL4,UAS-(BioUb)6-BirA/CyO flies
were additionally used as controls. UAS-GFP, elav-GAL4,
GMR-GAL4, Tub-GAL4, Da-GAL4, Ple-GAL4 flies were
obtained from Bloomington Drosophila Stock Center.
UAS-GFPCL1 flies were obtained from [48] and park25/
TM6b GFP-w+ and UAS-park were obtained from [16].
Flies were grown in 12 h light-dark cycles at 25 °C and
were fed with wheat flour and yeast food (1% agar, 5.5%
dextrose, 3.5% wheat flour, 5% yeast, 0.25% Nipagen,
0.4% Propionic acid and 0.02% Benzalkonium Chlor-
ide in distilled H2O).
Climbing assay
Flies of indicated ages and genotypes were anesthetised
with CO2 on a pad, and 20 flies (10 male and 10 female)
were randomly selected. After an hour of recovery, flies
were transferred to a climbing vial and ability to climb
was scored as followed. Flies were gently tapped to the
bottom and the number of flies that reached the 10 cm
mark at 30 s was counted three times, with 30 s interval.
Survival assay
One hundred newborn flies of the indicated genotypes
were maintained in wheat flour and yeast food in 12 h
light-dark cycles at 25 °C. The vials were changed every
2–3 days and the number of flies alive was counted.
Fly head extract preparation and cell lysis
Six heads (three males and three females) of adult flies
were cut and homogenised in 60 μL of 4x Laemmli buffer
with DTT. Samples were centrifuged 1 min at maximum
spin and the supernatant was recovered. Cells were har-
vested using “Hot Lysis buffer” (2% SDS, 50 mM NaF and
1 mM EDTA at 110 °C; Fig. 8). Protein concentrations
were determined by BCA protein assay (Pierce).
Cell culture, siRNA knockdown and transfection
hTERT-RPE1-Parkin cells [32, 49] were cultured in Dul-
becco’s modified Eagle’s medium (DMEM)/F12 with 10%
FBS, 1% non-essential amino acids and 1% penicillin/
streptomycin. Reverse transfection was performed using
Lipofectamine RNAi-MAX (Invitrogen) and carried out
for 72 h according to manufacturer’s instruction. Further
165 h double-hit knockdown was executed by transfect-
ing again previously siRNA treated cells at 72 h. Cells
were transfected with the following siRNA at a final con-
centration of 20nM: Non-Targeting siRNA oligo #1 (NT1)
(ONTARGETplus: NT1; 5’-UGGUUUACAUGTCGACU
AA-3’) and VPS35 (SMARTpool ONTARGETplus VPS35
siRNA oligo#5: 5’-GAACAUAUUGCUACCAGUA-3’;
oligo#6: 5’-GAAAGAGCAUGAGUUGUUA-3’; oligo#7:
5’-GUUGUAAACUGUAGGGAUG-3’; oligo#8: 5’-GAAC
AAAUUUGGUGCGCCU-3’) from Dharmacon.
Human neuroblastoma SH-SY5Y cells were cultured in
DMEM supplemented with 10% FBS (Thermo Scientific)
and 1:100 penicillin/streptomycin at 37 °C. 300,000 cells
were seeded in a 6 well-plate and incubated overnight
under serum starvation. The following day, medium was
removed, replaced by fresh DMEM and cells were trans-
fected with 1 μg of FLAG-Ub, 1 μg of YFP-VPS35 together
with 1 μg of pcDNA3.1 (control) or 1 μg of hParkin or
1 μg of hParkin (C431S) using Lipofectamine 3000 (Invi-
trogen) for 72 h according to manufacturer’s instruction.
GFP beads pull-down assay
Transfected cells were lysed in 500 μl of lysis buffer
[50 mM Tris–HCl pH 7.5, 150 mM NaCl, 1 mM EDTA,
0.5% Triton, 1 × Protease Inhibitor cocktail (Roche Applied
Science), 50 mMN-ethylmaleimide (NEM, from Sigma)]
and collected for centrifugation at 14,000 × g for 10 min.
The supernatant was mixed with 25 μL of GFP-Nanotrap
beads (Chromotek GmbH) that had been pre-washed with
dilution buffer (10 mM Tris–HCl pH 7.5, 150 mM NaCl,
0.5 mM EDTA, 1 × Protease Inhibitor cocktail, 50 mM
NEM). The mixture was incubated at RT for 150 min with
gentle rolling and centrifuged for 2,700 × g for 2 min. The
supernatant was removed and the beads washed once with
dilution buffer, three times with washing buffer (8 M Urea,
1% SDS in PBS) and once with 1% SDS in 1× PBS. The
bound proteins were eluted with sample loading buffer
(250 mM Tris–HCl pH 7.5, 40% glycerol, 4% SDS, 0.2%
BPB) by heating at 95 °C for 10 min. Eluted samples were
run into 4–15% Tris–Glycine gels.
Western blotting and silver staining
For fly samples the amount of sample loaded largely was
equivalent to one head per lane but was optimized for
each antibody. Generally, 4–15% gradient TGX gels
(Bio-Rad) were used and proteins were transferred to
PVDF membranes using the iBlot system (Invitrogen).
Following primary and secondary antibody incubation,
membranes were developed using ECL kit (Biorad Clarity).
Alternatively, western blots were scanned using the LI-
COR Odyssey system (LI-COR Biosciences). Silver staining
was performed with a SilverQuest kit (Invitrogen) follow-
ing the manufacturer’s instructions. Dual-colour westerns
were prepared by assigning independent colour channels
to two independent westerns developed in the same
membrane.
BioUb pulldown
The BioUb pulldown was performed as previously described
[39, 40, 43] using GMR-GAL4,UAS-(BioUb)6-BirA/CyO;
UAS-ParkinWT, GMR-GAL4,UAS-(BioUb)6-BirA/CyO;UAS-
ParkinLD, GMR-GAL4/CyO;UAS-BirA/TM6 and GMR-
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GAL4, UAS-(BioUb)6-BirA/CyO flies. Briefly, 2–5 day old
adult flies were fragmented by flash freezing in liquid nitro-
gen and shaking. A pair of sieves with a nominal cut-off of
710 and 425 μm was used to separate the heads from the
rest of the fragments. About 0.5 g of heads were homoge-
nized in 2.9 mL Lysis buffer (8 M Urea, 1% SDS and
50 mM N-ethylmaleimide in PBS, including a protease in-
hibitor mixture from Roche Applied Science). 250 μL of
NeutrAvidin-agarose beads (Thermo Scientific) were used
to purify BioUbiquitinated material and after stringent
washes with a succession of buffers containing 8.4 M urea,
6 M Gdn-HCl, 1 M NaCl and 2%SDS, beads were finally
eluted with 125 μL Elution Buffer (4X Laemmli Buffer and
100 mM of DTT). Recovered volume was ~150 μL with an
average yield of 20–40%.
Mass spectrometry
Eluted samples from three different experiments were
briefly run on a SDS-PAGE, which was then cut in four
slices, to separate the avidin band from the other pro-
teins in the gel. Proteins were digested using automated
in-gel digestion protocol [50]. The digested peptides
were cleaned-up on Stage-tips [51]. The eluted peptides
were resuspended in 0.1% formic acid and separated on
a 15 cm reverse phase column (75 μm inner diameter,
3 μm reprosil beads, Dr. Maisch, GmbH, in house
packed) using 5 to 50% acetonitrile gradient (VWR).
Peptide ionization was performed on a Proxeon ion-
source and sprayed directly into the mass spectrometer
(Q-Exactive, Thermo Scientific). The MS was recorded
with mass resolution of 60000, while the MS2 spectra
were collected with a resolution of 35000 using a fixed
fill time of 120 ms. For the analysis of the recorded mass
spectra the MaxQuant software package (version 1.2.2.5)
was used with 1% FDR for both peptides and proteins
[52]. Searches were performed using the Andromeda
search engine against the Uniprot Drosophila melanoga-
ster database (downloaded 15.08.2015). As a fixed modi-
fication, cysteine carbamidomethylation was selected
and as variable modifications, methionine oxidation,
protein N-terminal acetylation and di-glycine addition
on the ε-aminogroup of lysines. Two missed trypsin (full
specificity) cleavages were allowed and the MaxQuant
label free quantification for proteins was activated. The
identified ubiquitination sites were checked visually
using the Max-Quant View program and identification
artefacts were removed as previously described [53].
Ubiquitin chain linkage quantification
Samples from three technical replicates were loaded on
an 8% stacking gel and proteins compressed in one
band. Proteins were digested in-gel using trypsin, and
purified as described above. The peptides were separated
on a 25 cm reverse phase column (75 μm inner
diameter, 3 μm reprosil beads, Dr. Maisch, GmbH, in
house packed) using 5 to 50% acetonitrile gradient
(VWR). The peptides were ionized on a Nano3 ion
source (ABSciex) and directly sprayed into a QTRAP
5500 triple-quadrupole mass spectrometer, run in MRM
mode to detect branched ubiquitin peptides and their
synthetic isotopically labelled counterparts [54, 55]. Each
sample was injected as technical triplicates. Two transi-
tions for each peptide, i.e., K6, K11, K48, K63, were ac-
quired. After the measurement peaks were integrated
and light/heavy ratios calculated using the Skyline soft-
ware package [56] reflecting the abundance of the link-
age type compared to the internal heavy standard.
Bioinformatic and statistical analysis
Non-ubiquitinated/background proteins were excluded
by a 4-fold change threshold of the average LFQ inten-
sity between BioUb, BioUb + ParkinWT or BioUb + Par-
kinLD against the BirA sample. LFQ intensity values of
ubiquitinated proteins were imported to Perseus soft-
ware (http://www.perseus-framework.org/) and the im-
putation tool was used to replace missing values.
Subsequently, values were grouped in categories and two
T-tests were performed: BioUb + ParkinWT vs BioUb and
BioUb + ParkinWT vs BioUb + ParkinLD. Proteins with a p-
value smaller than 0.05 and a fold change bigger or
smaller than 2 in any of these two tests were selected for
further filtering. Proteins with less than two unique pep-
tides in all the three BioUb + ParkinWT (enriched) and
BioUb + ParkinLD (reduced) were excluded. To further
exclude false positives, all unique peptide profiles of
these proteins were analysed. Peptides that appeared
only in one condition were excluded and the average
peptide intensity was calculated for each peptide in each
condition. On the one hand, average of all peptide inten-
sities between BioUb + ParkinWT vs BioUb or BioUb + Par-
kinLD were calculated and only the proteins whose total
fold change was bigger (enriched) or smaller (reduced)
than two were further selected. On the other hand, the
average of all fold changes of peptide intensities between
BioUb + ParkinWT vs BioUb or BioUb + ParkinLD minus
the SEM (Standard Error of the Mean) was required
to be bigger or smaller than two. Only the proteins
that successfully passed all the tests were selected as:
Parkin substrates (35) and less ubiquitinated in a Par-
kin - dependent manner (2).
A two sample T-Test for Parkin proteomics was per-
formed using Perseus software applying default parameters:
t-test; S0; Side = both; threshold p-value = 0,05. Imputation
tool was used as default: width = 0,3; down shift = 1,8;
mode = separately for each column. Other statistical ana-
lysis was performed with Graphpad Prism6. For the GO
Term identification g:Cocoa tool of g:Profiler web server
was used using archive “Ensembl 79, Ensembl Genomes 26
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(r1395)”. p-values are indicated as *p ≤ 0.05, **p ≤ 0.01 and
***p ≤ 0.001. Functional connectivity analysis was per-
formed using STRING (http://string-db.org/) web tool.
For GFP pull-downs protein bands were analysed and
quantified by densitometry using ImageJ software. Statis-
tical significance in Western blotting quantification was
evaluated using an analysis of variance (ANOVA) com-
plemented by Tukey’s honest significance difference test
(Tukey’s HSD) performed in GraphPad PRISM software.
Statistical significance levels are annotated as ns, not sig-
nificant; **, p < 0.01 (mean ± SEM, n = 4).
Results
Excessive Parkin activity in developing neurons causes
climbing defects and reduced life span
In order to study Parkin E3 ubiquitin ligase activity in
Drosophila neurons, we over-expressed FLAG-ParkinWT
(Fig. 1a) and a catalytically inactive or ligase-dead
mutant, FLAG-ParkinLD, using the neuronal specific
elav-GAL4 driver (Fig. 1b). As expected, heterozygous
FLAG-Parkin flies expressed lower Parkin levels com-
pared to homozygous Parkin flies (Fig. 1c, Additional file
1: Figure S1A). Neuronal over-expression of ParkinWT
during Drosophila development compromises climbing
ability of the fly in an age and dose-dependent manner,
mirroring the phenotype of Parkin null flies (Fig. 1d,
Additional file 1: Figure S1B). Expression of a ligase-dead
form of Parkin generates a much milder climbing impair-
ment. The N-terminal FLAG tag did not contribute to this
behaviour as both untagged ParkinWT and 8HA-ParkinWT
flies display the same phenotype (Additional file 1: Figure
S1C). High-level expression of ParkinWT also led to a de-
creased life span (Fig. 1e) and, in distinction to ParkinLD
flies, ParkinWT flies displayed a Parkinsonian phenotype,
suffering from tremors and spontaneous spasms
(Additional file 12: Video S1).
Parkin substrate identification in adult Drosophila
neurons
We recently introduced a pipeline for the identification
of ubiquitinated proteins in a fly model that constitu-
tively expresses biotinylated ubiquitin (BioUb). Here, we
have applied this approach to identify physiologically
relevant Parkin substrates in adult Drosophila neurons
(Fig. 2a). BioUbiquitin together with either ParkinWT
(WT) or ParkinLD (LD) was over-expressed in Drosoph-
ila photoreceptors, a specialised type of neuron, using
GMR-GAL4 driver (Fig. 2b). Flies over-expressing just
BirA (C) and BioUbiquitin (Ub) were used as background
control and steady state ubiquitination control respect-
ively. Endogenous deubiquitinating enzymes (DUBs) di-
gest the BioUbiquitin construct releasing BirA (Fig. 2c) and
ubiquitin. Each ubiquitin contains a short N-terminal se-
quence, which is then recognised and biotinylated by
BirA, resulting in a biotin-tagged ubiquitin (BioUb) that is
efficiently handled by the cascade of ubiquitin conjugating
enzymes (Fig. 2d) [39–43]. BioUb conjugates were isolated
on Neutravidin beads (Fig. 2e, f ) and subsequently identi-
fied by Mass Spectrometry (MS).
Mass Spectrometry analysis of Parkin - dependent
ubiquitination identified novel putative Parkin substrates
in Drosophila neurons
Three independent experiments were performed for
each condition (Additional file 2: Figure S2A), generat-
ing 1522 protein identifications by mass spectrometry
(Additional file 9: Table S1). After background subtraction
of the BirA control, 1132 proteins were classed as ubiqui-
tinated by virtue of their enrichment (Fig. 3a). Most of the
ubiquitinated proteins were identified in each of the three
different conditions (Fig. 3b), suggesting that the ectopic
expression of Parkin does not perturb the overall global
ubiquitin economy. In fact, the number of proteins de-
tected to be ubiquitinated in each pulldown was very simi-
lar across all samples (Additional file 3: Figure S3A) and
Label Free Quantification (LFQ) values of independent
pulldowns were highly correlated (Additional file 4: Figure
S4). For proteins not directly quantitated in one experi-
mental condition (LFQ = 0) we used the Perseus imput-
ation tool to assign an arbitrary value within the lower
detection range (Additional file 3: Figure S3B).
Fifty-six proteins were discovered to be both more
than 2-fold enriched and reach a significance of p < 0.05
(Perseus T-test, see Materials and Methods). In contrast,
30 proteins were reduced (using the same criteria) in puri-
fied ubiquitinated material from ParkinWT over-expressing
neurons compared to controls (Fig. 4, Additional file 6:
Figure S6A). We next applied a further set of criteria to se-
lect the most robust Parkin responders (35 enriched, two
reduced). These all provide at least two unique peptides in
all three biological replicates and display a fold change big-
ger than two as average of all unique peptides (see Mate-
rials and Methods). Seven of the 35 enriched proteins are
annotated as mitochondrial proteins, 12 as cytosolic and 13
as part of endomembrane system according to UNIPROT
database (http://www.uniprot.org/) (Table 1, Additional file
10: Table S2). These include three sub-units of the v-
ATPase required for endosome and lysosomal acidification,
two proteins associated with the endosomal sorting
complexes required for transport (ESCRT) machinery
(ALiX, Vps4) and the PD-associated retromer component,
Vps35. The membrane receptor NinaE (Opsin/Rhodopsin
homolog) and the cytosolic calcium binding protein,
Cbp53E are robustly, less ubiquitinated in a Parkin E3 ubi-
quitin ligase activity dependent manner.
Trypsin treatment of ubiquitinated proteins leaves a
di-Gly signature residue at the ubiquitination site. Al-
though the majority of peptides we use for quantitation
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are not themselves ubiquitinated, we have captured a set
of 111 ubiquitinated peptides (Additional file 11: Table
S3). Such di-Gly peptides were detected for five of the
Parkin substrates identified as described above (Cisd2,
EIF2B-beta, Pdh, Porin and SesB) and for the two proteins
that were less ubiquitinated in a Parkin context (NinaE
and Cbp53E) (Fig. 5). Di-Gly peptides corresponding to
the following ubiquitination sites, Cisd2 K83, EIF2B-beta
K30, Pdh K40, Porin K52 and SesB K120 were enriched in
ParkinWT over-expressing flies. However, Pdh K85 was
found in a Parkin-independent manner, as similar inten-
sities were detected in all samples. Di-Gly peptides for
Cbp53E K262 and NinaE K372 were reduced in ParkinWT
flies. Moreover, 3 di-Gly peptides within Parkin itself were
also detected that showed differing enrichment patterns.
K35 was more ubiquitinated in ParkinWT compared to
both ParkinLD and control. K40 was similarly ubiquiti-
nated in ParkinWT and ParkinLD, but not in control
and K128 was much more ubiquitinated in ParkinLD
compared to ParkinWT and control.
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Fig. 1 Parkin over-expression in developing neurons causes severe climbing defects and premature death in Drosophila melanogaster. a Domain
structure of Drosophila melanogaster Parkin, cloned with a N-terminal FLAG tag. The catalytic cysteine (C449), marked with an asterisk, was mutated to
serine to generate a Ligase-Dead (LD) Parkin mutant. b L3 larva showing GFP over-expression pattern in developing neurons using the elav-GAL4
driver. c Anti-Parkin western blot showing Parkin levels in flies over-expressing one copy (ParkinWT/+ and ParkinLD/+) or two copies of FLAG-tagged
WT (ParkinWT) and LD Parkin (ParkinLD), using elav-GAL4. GFP over-expression was used as a control. Four-fold less sample was loaded for ParkinWT and
ParkinLD. d Climbing assay of stated genotypes at 5–8 and 17–20 days after eclosion. Parkin null (park25) flies were used as a negative control. Stars
indicate 0% climbing ability and a skull represents complete death at the particular time point. Three technical replicates were performed with three
biological replicates of each genotype and age. Columns represent average values and error bars show standard error of the mean (SEM). e Survival
assay of stated genotypes. Survival graphs represent % of alive flies at each time point. Statistical significance was assessed by two-tailed paired
Student’s-t test. Asterisk(s) indicate significance, *p≤ 0.05, **p≤ 0.01 and ***p≤ 0.001. Complete genotypes of flies used: elav-GAL4,UAS-GFP/CyO (GFP),
elav-GAL4/CyO;UAS-ParkinWT/TM6 (ParkinWT/+), elav-GAL4/CyO;UAS-ParkinLD/TM6 (ParkinLD/+), elav-GAL4/CyO;UAS-ParkinWT (ParkinWT), elav-GAL4/CyO;UAS-
ParkinLD (ParkinLD) and park25 (Parkin null)
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Parkin preferentially generates K6 ubiquitin chains in
Drosophila neurons
Ubiquitin chains can be assembled through isopeptide
bonds with any of the seven internal lysine residues.
Each linkage type generates a unique peptide signature
upon trypsin digestion that can be discriminated by
mass spectrometry and quantitated by comparison with
isotopically labelled standard [55]. We adopted this
strategy to identify the linkage types of the ubiquitin
chains that are generated by Parkin over-expression in
vivo, by analysis of isolated BioUb material. As judged by
western blotting neither the overall pattern of ubiquiti-
nation nor the total amount of ubiquitinated material
were altered by ParkinWT over-expression in Drosophila
neurons (Fig. 6a). The same conclusion can be obtained
based on the Venn diagrams that compare the ubiqui-
tomes identified upon Parkin over-expression with the
control samples (Fig. 3b). However, we find a marked in-
crease in the representation of K6 linked ubiquitin
chains in ParkinWT compared to control BioUb and
ParkinLD samples (Fig. 6b, Additional file 6: Figure S6B).
Validation of Parkin candidate substrates
We sought to validate ubiquitination of selected Parkin
substrates by direct western blotting of proteins for
which antibodies were available. For ArgK, RdhB and
Vps4 we observe a fraction that is uniformly upshifted to a
degree consistent with monoubiquitination in a manner
that is stringently dependent on Parkin activity (Fig. 7a). In
contrast, Fax, a protein that was not specifically enriched
following Parkin expression in the mass spectrometry data
set, is indiscriminately ubiquitinated in all samples (Fig. 7b).
Parkin is enriched largely in an unmodified form in the el-
uates of flies over-expressing Parkin (Fig. 7c). This likely
represents Parkin that is captured by virtue of a thioester-
bonded ubiquitin at its active site cysteine, which is then
released by the reducing conditions of the subsequent pro-
cessing steps. The residual minor ubiquitinated fraction is
linked via isopeptide bonds, suggesting that a small fraction
of Parkin is itself ubiquitinated.
Parkin-dependent Vps35 ubiquitination could not be val-
idated in flies by western blotting, due to the lack of avail-
able working antibodies for Drosophila Vps35. We instead
performed in human cells an in vivo ubiquitination assay
we recently developed [42, 43, 57, 58]. The main advantage
of this method is that, due to the very stringent washes
performed, the entire ubiquitin signal detected corresponds
exclusively to the protein of interest and cannot be derived
from other proteins in the cell. We tested this assay on
SH-SY5Y neuroblastoma cells, which allowed us to further
test whether Parkin-dependent ubiquitination of VPS35 is
conserved in human cells.
(See figure on previous page.)
Fig. 2 Proteomic analysis of Parkin substrates in Drosophila melanogaster neurons. a Scheme of the strategy used to identify proteins
ubiquitinated by Parkin in Drosophila neurons. FLAG-tagged Parkin WT or LD flies also expressed biotin modified ubiquitin (BioUb) in Drosophila
photoreceptors using GMR-GAL4 driver (image shows GFP expression with GMR-GAL4 in an adult fly head). BioUbiquitinated material was purified using
Neutravidin beads and isolated material was analysed by Mass Spectrometry (MS). Ubiquitinated proteins enriched in Parkin WT over-expressing
neurons were then identified based both on protein LFQ levels and peptide intensities. b Anti-Parkin immunoblotting shows Parkin levels in head
extracts of GMR-GAL4/CyO;UAS-BirA/TM6 (C), GMR-GAL4,UAS-(BioUb)6-BirA/CyO (Ub), GMR-GAL4,UAS-(
BioUb)6-BirA/CyO;UAS-Parkin
WT (WT) and GMR-
GAL4,UAS-(BioUb)6-BirA/CyO;UAS-Parkin
LD (LD) flies. Parkin null (park25) flies were used as a negative control. WT and LD samples were diluted 100 times.
c Anti-BirA western blot of C, Ub, WT and LD heads extracts. d Anti-Biotin western blot of C, Ub, WT and LD heads extracts. e C, Ub, WT, LD fly heads
were subjected to BioUb pulldown. Input (1/100), Flowthrough (FT, 1/100) and Elution (1/400) were immunoblotted for biotin. f Silver staining of C, Ub,
WT, LD BioUb pulldown elutions (undiluted). In panels B through F, arrowheads indicate ectopic Parkin; arrow indicates endogenous Parkin; smear
highlighted by the brace represents BioUbiquitinated material; and the asterisk shows an endogenously biotinylated protein
A) 
Identified proteins 
1522 
1096 proteins  
in BioUb+ParkinLD
1077 proteins  
in BioUb+ParkinWT
1056 proteins  
in BioUb
Ubiquitome
B) 
Background 
390 
Ubiquitinated
1132 
Fig. 3 Characteristics of the data set. a Three independent BioUb pulldowns were performed for each condition generating 1522 protein
identifications by mass spectrometry of which 1132 were considered to be ubiquitinated by imposing a threshold of four-fold change in LFQ
intensity relative to BirA control. b Venn diagram shows the overlap between proteins identified as ubiquitinated under different conditions,
indicating that Parkin expression does not dramatically alter the global ubiquitome
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SH-SY5Y cells were transfected with YFP-VPS35,
FLAG-Ub and either WT or LD untagged human Parkin.
Cells were then subjected to a GFP pulldown and the
eluted samples monitored by Western blotting in order to
compare ubiquitination levels of VPS35 across the differ-
ent samples (Fig. 8a, Additional file 7: Figure S7). Since
the ubiquitination signal proceeds only from YFP-VPS35,
quantification of the data (Fig. 8b) is provided as ratios
of the ubiquitin signal (monitored through the anti-Flag
western) over the VPS35 intensity (monitored through the
anti-GFP western). A significant increase in the ubiquiti-
nated fraction of VPS35 was observed when WT Parkin
was co-expressed, relative to either control (only endogen-
ous Parkin or LD Parkin co-expression).
VPS35 knockdown does not affect Parkin - dependent
mitophagy in YFP-Parkin expressing RPE1 cells
Our results confirm a linkage between Parkin and the
PD-associated protein VPS35, which has been previously
revealed by genetic studies [59]. Both the proteomic data
and the in vivo ubiquitination assay coupled to subsequent
western blot validation suggest that VPS35 may be a sub-
strate of Parkin, in line with previous studies that analysed
Parkin substrates following acute mitochondrial depolar-
isation [38]. The mechanism that links VPS35 to PD is
unclear, although recent evidence indicates that
VPS35 regulates mitochondrial homeostasis by regu-
lating fission-fusion dynamics [60, 61] and the traf-
ficking of mitochondrial-derived vesicles (MDV) [62, 63].
We and others have recently used retinal pigment epithe-
lial cells (RPE1) that stably over-express YFP-Parkin as a
convenient system for analysis of Parkin-dependent mito-
phagy [32, 49]. We tested whether VPS35 is necessary for
PINK1/Parkin - dependent mitophagy in these cells fol-
lowing acute mitochondrial depolarisation. However,
siRNA-mediated knockdown of VPS35 had no effect
upon mitophagy as judged by the time-dependent loss
of several mitochondrial marker proteins (Fig. 8c).
Log2 Fold change LFQ intensity of ParkinWT vs ParkinLD
P-value 
- - - 
Fig. 4 Distribution of ubiquitinated proteins according to Parkin catalytic activity. Volcano plot showing the outcome of the ParkinWT vs ParkinLD
T-test performed with Perseus. Proteins are distributed along x axis by fold change of LFQ intensity and y axis by p-value. Proteins in bold,
represent the most robust Parkin responders (35 enriched and 2 reduced - Table 1) whose LFQ change at the protein level is also coherently
detected at the peptide level (Additional file 5: Figure S5)
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Discussion
Parkin regulates a delicate balance between survival and
cell death
Our finding that neuronal Parkin over-expression during
neurodevelopment leads to multiple Parkinsonian-like
defects conflicts with the simple notion that Parkin is
neuroprotective [29]. However, recent cell culture and in
vivo studies have shown that Parkin activity can also
sensitize towards cell death in certain contexts [30–33].
We observed that the severity of Parkin over-expression
phenotype is associated with its E3 ubiquitin ligase activ-
ity in a dosage dependent manner, which is further aug-
mented during aging. Nevertheless, the fact that flies
over-expressing ParkinLD still have a mild phenotype,
Table 1 The most robust Parkin responders identified in Drosophila neurons
Proteins that are significantly more (green) and less (red) enriched in purified ubiquitinated material in a Parkin-dependent manner are shown in this table. Fold
change refers to ParkinWT vs ParkinLD ratio in natural scale. Unique peptides found in the whole proteomic analysis are indicated. Human homolog genes were
identified using g:Orth tool of web server g:Profiler. Cellular Compartment (CC) information was obtained from UniProt and is based on the human homolog.
Cytosolic (Cyt), Mitochondrial (Mit), Endomembrane system (End), Extracellular (Ext), Peroxisomal (Per), Nuclear (Nuc) and Plasma Membrane (PM). Bold proteins
represent known substrates and underlined proteins have been previously detected as more ubiquitinated in Parkin samples in previous Parkin proteomic studies
in cell culture [37, 38]. *Cellular Compartment depends on the selected human homolog
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Fig. 5 (See legend on next page.)
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suggests that this mutant shows a dominant-negative ef-
fect that is not linked to the ligase function. Further in
vivo experiments are necessary to unravel Parkin function
at different developmental stages in different tissues.
Functional roles of identified substrates
Identification of Parkin substrates is crucial in order to
comprehend the still elusive aetiology of PD. While early
studies stressed the notion that Parkin ubiquitinates and
degrades several aggregation-prone toxic proteins, cur-
rently Parkin is mainly associated with mitophagy,
through ubiquitination of several OMM proteins [35, 36,
64–66]. Parkin is predominantly held in an inactive con-
formation at steady state [20] and PINK1 dependent
phosphorylation of both ubiquitin and Parkin is neces-
sary for its activation [19–25]. Mitochondrial depolari-
sers have been proven to efficiently activate Parkin
through PINK1 accumulation, but most cell lines show
low levels of Parkin, precluding detectable levels of
Parkin-dependent mitophagy and ubiquitination. More-
over, the ubiquitinated fraction of proteins is usually low
due to their fast proteasomal degradation and/or the ac-
tivity of deubiquitinating enzymes (DUBs) [67]. There-
fore, most studies have been performed under conditions
of Parkin over-expression using non-neuronal in vitro cell
culture models, usually employing proteasome inhibitors
and mitochondrial depolarisers. However, these acute con-
ditions are not encountered in physiological settings. In
the present study we have sought for in vivo Parkin sub-
strates in Drosophila neurons, using a fly model that co-
expresses constitutively biotinylated ubiquitin together
with FLAG-tagged Parkin. While it has been shown that
tagging human Parkin can lead to some constitutive acti-
vation [68], Drosophila Parkin has an extended N-
terminal sequence relative to the human protein and
addition of a further short sequence tag is not predicted to
impact on the structure (Additional file 8: Figure S8). If
such a scenario was extant, it would simply shift an equi-
librium and potentially allow more sensitive detection of
Parkin substrates without the recourse to acute drug treat-
ments used in previous studies [27, 34, 36–38]. Treat-
ments with mitochondrial depolarising drugs will lead to
(See figure on previous page.)
Fig. 5 Peptide profile of robust Parkin responders encompassing a Di-Gly peptide. Di-Gly peptides were detected for 5 of the Parkin substrates
identified: Cisd2, EIF2B-beta, Pdh, Porin and SesB. Moreover, Cbp53E and NinaE, whose ubiquitination robustly decreases in a Parkin E3 ubiquitin
ligase activity dependent manner, also provided a di-Gly peptide. Three ubiquitination sites were also detected in Parkin itself. The graph represents
the peptide intensity of all the unique peptides that were assigned to the indicated protein in each condition (grey dots). Di-Gly peptides are shown in
blue and the average peptide intensity in red
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Fig. 6 Parkin preferentially generates K6 ubiquitin chains. a C, Ub, WT,
LD heads were subjected to BioUb pulldown and inputs and elutions
were immunoblotted for ubiquitin. b C, Ub, WT, LD fly heads were
subjected to BioUb pulldown and signature ubiquitin chain peptides
were quantitated by comparison with isotopically labelled standards
using mass spectrometry. Graph shows fold change of ubiquitin chain
linkages found in ParkinWT vs BioUb. Error bars indicate standard
deviation of three technical replicates. Complete genotypes of flies
used: GMR-GAL4/CyO;UAS-BirA/TM6 (C), GMR-GAL4,UAS-(BioUb)6-BirA/CyO
(Ub), GMR-GAL4,UAS-(BioUb)6-BirA/CyO;UAS-Parkin
WT (WT) and GMR-
GAL4,UAS-(BioUb)6-BirA/CyO;UAS-Parkin
LD (LD)
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Fig. 7 WB validation of in vivo Parkin substrates. C, Ub, WT, LD fly
heads were subjected to BioUb pulldown and Inputs and Elutions
were immunoblotted for a RdhB, ArgK and Vps4; b Fax; c Parkin. WT
and LD input and elution samples were diluted 50 and 25 times,
respectively. Arrowheads show unmodified protein and arrows
indicate ubiquitinated protein. Asterisks indicate unspecific bands.
Complete genotypes of flies used: GMR-GAL4/CyO;UAS-BirA/TM6 (C), GMR-
GAL4,UAS-(BioUb)6-BirA/CyO (Ub), GMR-GAL4,UAS-(
BioUb)6-BirA/CyO;UAS-
ParkinWT (WT) and GMR-GAL4,UAS-(BioUb)6-BirA/CyO;UAS-Parkin
LD (LD)
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PINK1 accumulation and activation of Parkin specifically
at mitochondria. Our study provides a complementary re-
source, which may capture some Parkin substrates that
are PINK1-independent. The notion of alternative activa-
tion routes for Parkin has been previously proposed [69]
and it is supported by data suggesting a role for Parkin in
xenophagy that might be PINK1-independent [70].
We identified 37 proteins whose ubiquitination pattern
changes in a Parkin E3 ubiquitin ligase activity dependent
manner. 35 proteins were enriched and 2 were reduced in
purified ubiquitinated material of Parkin over-expressing
head extracts (Fig. 9). Western blot validation of proteins
for which Drosophila antibodies were available confirmed
several of these proteins as authentic in vivo Parkin sub-
strates. A number of mitochondrial proteins were identi-
fied, including proteins known to be ubiquitinated during
mitophagy, such as Cisd2/CISD1,2 (MitoNEET), Porin/
VDAC1,2,3 and Tom70 [27, 34, 36–38, 71]. Nevertheless,
in comparison to other recent Parkin proteomic studies,
our Parkin substrate data set shows less enrichment of
mitochondrial proteins, probably reflecting the lack of
acute mitochondrial depolarization [27, 34, 37, 38]. Whilst
some of the mitochondrial proteins are ultimately matrix
associated, they are synthesised in the cytosol and
imported through the TIM/TOM complex providing the
opportunity to encounter cytosolic Parkin. Interestingly,
the presence of ubiquitinated proteins within the yeast
mitochondrial matrix has recently been reported [72].
In fact, a recent paper suggested that Parkin ubiquiti-
nates and regulates the stability of the mitochondrial
matrix enzyme 17-β hydroxysteroid dehydrogenase
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Fig. 8 Human Parkin and VPS35 interaction: VPS35 is ubiquitinated
by wild type Parkin in human cells. a VPS35 is ubiquitinated by
untagged WT Parkin in SH-SY5Y cells. YFP-VPS35 showed a significant
increase in its ubiquitinated fraction when it is over-expressed with wild
type untagged hParkin (WT), as shown with anti-FLAG (to FLAG-Ub)
antibody Western blot (red) compared to control (C) or the single point
(C431S) mutated hParkin (LD). The non-modified form of VPS35 was
detected by GFP antibody (green). The bottom panel shows levels of
Parkin protein in the whole cell extract before the isolation of the
GFP-tagged proteins. The endogenous Parkin protein is barely detected.
b Quantification of the ubiquitination status of VPS35 relative to the
non-modified form was performed calculating the ratio FLAG:GFP
with Image-J. The plot shows relative levels of VPS35 ubiquitination
normalized to the GFP levels. Statistical significance in Western blotting
semi-quantification was evaluated using an analysis of variance (ANOVA)
complemented by Tukey’s honest significance difference test (Tukey’s
HSD) performed in GraphPad PRISM software. Statistical significance
differences (**, p < 0.01 (mean ± SEM, n= 4)) were observed for the WT
Parkin sample relative to both control and LD Parkin samples. For LD
Parkin sample ns indicates not significant differences relative to the
control sample. c VPS35 knockdown does not affect Parkin - dependent
mitophagy. hTERT-RPE1 cells stably over-expressing YFP-Parkin were
subjected to control and VPS35 siRNA for 72 h or 165 h and treated
with 10 μM CCCP for 2, 8 and 24 h. Samples were immunoblotted as
indicated. High exp: high exposure
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Fig. 9 Functional connectivity of the most robust Parkin responders
identified in Drosophila neurons. Cellular compartment representation
of 35 enriched (green) and 2 reduced (red) human homolog proteins
in purified ubiquitinated material from ParkinWT over-expressing
Drosophila neurons (Table 1). STRING (http://string-db.org/) analysis
based on experimental data shows the connectivity. Strength of dotted
lines represents differential significance (darker lines show higher
significance). Yellow circles indicate ParkinWT dependent ubiquitination
sites identified in Drosophila proteins
Martinez et al. Molecular Neurodegeneration  (2017) 12:29 Page 13 of 19
type 10 (HSD17B10) [73]. Further proteins previously de-
tected also include Sply/SGPL1, VPS4, VPS35, ALiX/
PDCD6IP and CG5525/CCT4 [37, 38]. To our knowledge,
the remaining 27 enriched proteins are novel Parkin sub-
strates, which are predominately cytosolic and endosomal
proteins. Inversely, NinaE/Opsin, Rhodopsin and Cbp53E/
Calbindin were reduced in purified ubiquitinated material
after Parkin over-expression indicating that Parkin can
indirectly regulate the ubiquitination status of these pro-
teins. It is also plausible that Parkin-dependent ubiquitina-
tion followed by rapid degradation result in reduced
protein levels leading to decreased ubiquitination sta-
tus of these substrates. Importantly, decreased calbindin
mRNA and protein levels are linked to neurodegeneration
in PD [74–77].
The fact that there is no singular pathway controlled
by substrates described here suggests that under in vivo
physiological conditions Parkin may have broader roles
beyond the control of mitophagy. For example, we note
prominent representation of endosomal-associated pro-
teins, including three sub-units of the v-ATPase required
for endosome and lysosomal acidification, two proteins as-
sociated with the endosomal sorting complexes required
for transport (ESCRT) machinery (ALiX/PDCD6IP, VPS4)
and the PD-associated gene and retromer component
VPS35. Moreover, proteins involved in protein synthesis,
metabolic process, cell death, calcium signaling and im-
mune response are also present (Additional file 10: Table
S2). Further study of Parkin substrates will reveal whether
they act in an unexplored common pathway.
Parkin monoubiquitinates substrates and preferentially
generates K6 ubiquitin chains
A single ubiquitin can be attached to a unique (monou-
biquitination) or several (multiple-monoubiquitination)
lysine residues of substrate proteins. Ubiquitin can be
generated from these stubs to form chains of different
topologies (M-1, K6, K11, K27, K29, K33, K48, K63).
This provides a complex “ubiquitin code” that regulates
a myriad of biological processes. Whilst K48 regulates
protein turnover, through proteasomal degradation, and
K63 is mainly involved in endosomal trafficking and
DNA repair, the function of the “non-canonical” chains
is less well defined [78, 79]. Parkin has been reported to
be able to promote monoubiquitination as well as mul-
tiple chain types such as K6, K11, K27, K48 and K63
ubiquitin chains in diverse contexts through interaction
with different E2s [64, 80–83]. Moreover, Parkin has
been shown to autoubiquitinate itself via K6 ubiquitin
chains and the deubiquitinase USP8 has been suggested
to remove these K6 chains to regulate Parkin stability
and its recruitment to mitochondria [84]. Furthermore,
USP15, USP30 and USP35 have been shown to deubi-
quitinate Parkin substrates and/or regulate mitophagy
following acute mitochondrial depolarisation in cells [32,
38, 85, 86]. While USP15 has been reported to have a
preference for K48 and K63 [85], USP30 has been re-
ported to favour K6 chains disassembly [87].
In contrast to our earlier work using this same bioUb
pulldown and Western blotting approach [39, 40, 42, 43],
most of the specific proteins we have validated here by
western blotting were found to be monoubiquitinated.
This agrees with previous observations demonstrating that
Parkin is able to generate monoubiquitinated conjugates
[81, 82]. Our ubiquitin chain analysis showed that Parkin
preferentially promotes K6 chain formation in contrast to
some literature reports indicating that Parkin promotes a
more diverse set (K6, K11, K48 and K63) after mitochon-
drial depolarisation [83, 88]. However, in line with our ob-
servations, recent ubiquitin chain analysis showed that K6
is preferentially formed in whole lysates from Parkin over-
expressing HEK and SH-SY5Y cells after mitochondrial
depolarisation [87].
Implications of Parkin-dependent VPS35 ubiquitination in
neurodegeneration
Despite the fact that the exact molecular mechanism
leading to PD is unclear, the set of genes linked to PD
can be divided in two main pathways. Parkin, DJ-1,
PINK1 and FBXO7 are linked to mitochondrial homeo-
stasis [65, 66, 89, 90], while α-synuclein (SNCA), LRRK2,
VPS35, EIF4G1 and ATP13A2 are involved in
endosomal-lysosomal trafficking [7–9]. LRRK2, RAB7L1
and VPS35 have been shown to act in a common
pathway [91, 92] and VPS35 has recently been shown to
genetically interact with EIF4G1 in a pathway upstream
of α-synuclein [93]. Furthermore, VPS35 impairment
leads to lysosomal dysfunction and α-synuclein path-
ology [94, 95].
The finding that Parkin ubiquitinates VPS35 is of con-
siderable interest, as it could represent a connection be-
tween mitochondrial homeostasis and endo-lysosomal
pathways, unifying the PD-associated genes in a com-
mon network [96]. In fact, recent studies in Drosophila
reported that Vps35 genetically interacts with parkin
[59]. Our identification of VPS35 as a Parkin substrate
strengthens this association. Moreover, VPS35 has been
found to be involved in mitochondrial homeostasis [60, 61],
therefore it is tempting to consider that Parkin-dependent
ubiquitination of VPS35 may regulate mitophagy. However,
our results show that Parkin-dependent mitophagy is not
affected by VPS35 knockdown, suggesting that VPS35 is
not an essential regulator of Parkin-dependent mitophagy
in a mammalian cell system subjected to acute depolarisa-
tion. Nor do we see any changes in VPS35 levels following
Parkin activation (Fig. 8c) or with control RPE-1 cells which
do not express Parkin (not shown). Alternatively, Parkin -
dependent-ubiquitination of VPS35 could be involved in
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the regulation of mitochondrial-derived vesicles (MDV),
which have been reported to traffic defective mitochondrial
proteins to peroxisomes and lysosomes in a more specific
manner prior to the whole organelle impairment [62, 63,
97]. A further possibility is that Parkin ubiquitinates and
regulates endo-lysosomal pathway components through the
ubiquitination of several proteins, including VPS35 and
others described here. During the preparation of this manu-
script Parkin has been reported to modulate endo-
lysosomal trafficking through Rab7 ubiquitination, but also
to influence the distribution of VPS35 and the levels of the
retromer cargo protein ci-M6PR [98]. Other recent papers
have also linked Parkin to endo-lysosomal trafficking
[99–102]. The involvement of endocytic trafficking in PD
is gaining momentum with the finding that two main PD-
associated genes, PINK1 and LRRK2, converge and lead to
the phosphorylation of common Rab proteins, small
GTPases involved in membrane trafficking [103–105].
Interestingly, both VPS35 and Parkin mutations are also
associated with Alzheimer’s Disease (AD) [106–108].
VPS35 interacts with the amyloid precursor protein (APP)
sorting receptor, SorL1, which is also an AD causing gene,
to regulate APP processing and Aβ production [109–113].
Parkin has recently been identified as an AD risk gene
[108] and decreased Parkin levels have been found in AD
patient cerebrospinal fluids [114]. Remarkably, Parkin
over-expression has been shown to ameliorate AD
symptoms by increasing the clearance of amyloid loads
[115, 116], which may suggest that defects in a common
endo-lysosomal pathway are shared between PD and AD.
In this scenario, Parkin may have a role in endosomal traf-
ficking control through ubiquitination of VPS35, with a
potential impact on both PD and AD. Certainly, further
work is required in order to explore this hypothesis.
Conclusion
Constitutive expression of biotinylated ubiquitin has
been proven to be a successful approach to study ubiqui-
tination in vivo [39, 40, 43]. Here we extend this method
to identify Parkin substrates in adult Drosophila neu-
rons. We report 35 substrates, eight of which have been
previously detected and 27 are novel. Notably we identi-
fied VPS35 as an in vivo Parkin substrate, both in flies
and in human neuroblastoma SH-SY5Y cells, reinforcing
a connection between mitochondrial homeostasis and
endo-lysosomal pathways in PD and AD.
Additional files
Additional file 1: Figure S1. Parkin over-expression in developing
neurons causes severe climbing defects. A) Anti-Parkin and Syntaxin1A
western blot of stated genotypes. Head extracts of flies over-expressing
two copies of Parkin (ParkinWT and ParkinLD) were diluted 4 times. B)
Whole climbing assay shown in Fig. 1d. Stars indicate 0% climbing ability
and a skull represents complete death at the particular time point. C)
GFP, Flag-ParkinWT, Flag-ParkinLD, untagged ParkinWT R1, ParkinWT R2,
8HA-Parkin WT/+ (one copy) and 8HA-Parkin WT (two copies) constructs
were expressed with elav-Gal4. Climbing assay of stated genotypes was
performed as well as western blot for Parkin and Syx1A. ParkinWT R1,
ParkinWT R2 are elav-Gal4 recombined versions of parkin from [16]. Three
technical replicates were performed with three biological replicates of
each genotype and age. Columns represent average values and error bars
show standard error of the mean (SEM). Statistical significance was assessed
by two-tailed paired Student’s-t test. Asterisk(s) indicate significance, *p≤ 0.05,
**p≤ 0.01 and ***p≤ 0.001. Complete genotypes of flies used: elav-GAL4,UAS-
GFP/CyO (GFP), elav-GAL4/CyO;UAS-ParkinWT/TM6 (ParkinWT/+), elav-GAL4/
CyO;UAS-ParkinLD/TM6 (ParkinLD/+), elav-GAL4/CyO;UAS-ParkinWT (ParkinWT), elav-
GAL4/CyO;UAS-ParkinLD (ParkinLD) and park25 (Parkin null), elav-GAL4,UAS-Parkin/
CyO (Parkin R1, R2), elav-GAL4/CyO;UAS-8HAParkinWT/TM6 (8HA-Parkin/+) and
elav-GAL4/CyO;UAS-8HAParkinWT (8HA-Parkin). (PDF 268 kb)
Additional file 2: Figure S2. Control western blots A) The complete
gel of Fig. 2f showing the three independent BioUb pulldown
experiments analysed by MS for Parkin substrate identification. B) All
individual loading controls (actin western blots) for Fig. 8. (PDF 337 kb)
Additional file 3: Figure S3. Reproducibility of the system I. A) Venn
diagrams show number of proteins detected in each BioUb pulldown
analysed by MS for Parkin substrate identification. B) LFQ intensity
distribution of identified proteins in all BioUb pulldowns used for Parkin
substrate identification with Perseus software. Non-inputated values are
shown in green and inputated values in red. Note that Perseus replaced
LFQ intensities that displayed a value of 0 by low value intensities within
the lower detection limit according to a normal distribution. LFQ
intensities are displayed in Log2 scale. (PDF 785 kb)
Additional file 4: Figure S4. Reproducibility of the system II.
Multicorrelation graph of LQF intensities of proteins identified in all BioUb
pulldowns analysed by MS for Parkin substrate identification. LFQ
intensities are displayed in Log2 scale. (PDF 149 kb)
Additional file 5: Figure S5. Peptide validation to identify the most
robust Parkin responders. According to Perseus T-Test (Fold change >2,
p-value < 0.05), 51 and 11 proteins were significantly more or less
enriched respectively in purified ubiquitinated material of Parkin over-
expressing head extracts, in a Parkin-dependent manner at the protein
level with at least 2 unique peptides in all three relevant conditions (for
enriched ParkinWT and for reduced ParkinLD). To further identify which are
the ones that are more robustly associated to Parkin activity, the peptide
profile of each of those proteins was analysed (see material and
methods). A) Intensities of all the unique peptides in each condition
(grey dots) and the average peptide intensity (red) are represented for
each protein. When present, di-gly peptides are showed in blue. B) Fold
change of all the unique peptides in each condition (grey dots) and
the average fold change and standard error of the mean (SEM) are
represented in red. Average intensity of the three replicates was used per
condition and only peptides that appeared at least in two conditions
were used. (PDF 3020 kb)
Additional file 6: Figure S6. Proteins that are specifically more
ubiquitinated after Parkin expression in two independent analyses
and supplementary Ub chain graph. A) Outcome of two T-tests per-
formed with Perseus are plotted in this volcano plot: ParkinWT vs Par-
kinLD (left side) and ParkinWT vs Control (BioUb; right side). Proteins
are distributed along x axis by fold change of LFQ intensity and y
axis by p-value. Proteins with a fold change bigger than 2 and a p-
value lower than 0.05 are labelled with their names in grey. Proteins
in bold, represent the most robust Parkin responders (see Table 1,
Additional file 5: Figure S5). Fold change of LFQ intensity is repre-
sented in Log2 scale. B) C, Ub, WT, LD fly heads were subjected to
BioUb pulldown and ubiquitin chains present in elutions were quanti-
tated by comparison with isotopically labelled standards. Graph
shows fold change of ubiquitin chain linkages found n ParkinWT vs
ParkinLD. Error bars indicate standard deviation of three technical rep-
licates. Complete genotypes of flies used: GMR-GAL4/CyO;UAS-BirA/TM6
(C), GMR-GAL4,UAS-(BioUb)6-BirA/CyO (Ub), GMR-GAL4,UAS-(
BioUb)6-BirA/
CyO;UAS-ParkinWT (WT) and GMR-GAL4,UAS-(BioUb)6-BirA/CyO;UAS-Par-
kinLD (LD). (PDF 414 kb)
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Additional file 7: Figure S7. Over-expression of hParkin (WT) induced
an increase of VPS35 ubiquitination compared to control (C) or to over-
expression of inactive hParkin (LD) in four independent experiments. (A)
The complete gels of Fig. 8a showing four independent in vivo ubiquitination
assays for VPS35 in SH-SY5Y cells. Ubiquitination of YFP-tagged VPS35 was
analysed by Western blot after capture of the YFP-tagged protein. Mouse
anti-GFP antibody was used for detecting the captured VPS35 (shown
in green), and HRP-conjugated anti-FLAG antibody for monitoring its
ubiquitinated fraction (shown in red). Untagged Parkin over-
expression levels in the whole cell extracts are monitored with anti-Parkin
antibody. (B) Quantification of the ubiquitination status of VPS35 relative to
the non-modified form was performed calculating the ratio FLAG:GFP with
Image-J. The plot shows relative levels of VPS35 ubiquitination normalized
to the GFP levels. (PDF 14700 kb)
Additional file 8: Figure S8. Alignment of Human and Drosophila
Parkin. (PDF 61 kb)
Additional file 9: Table S1. All proteins identified: Details of all proteins
identified in the whole mass spectrometry analysis. Proteins are divided
in Background and Hits (Ubiquitinated). (XLS 2430 kb)
Additional file 10: Table S2. The most robust Parkin responders
identified in Drosophila neurons: Details of the most robust Parkin
responders identified in Drosophila neurons. (XLS 58 kb)
Additional file 11: Table S3. Di-gly Sites: Details of all detected Di-gly
peptides. (XLS 154 kb)
Additional file 12: Video S1. Parkin over-expression in neurodevelop-
ment results in Parkinsonian-like defects: Empty vials containing 5 male
and 5 female, 0–3 days after eclosion flies of elav-GAL4/CyO;UAS-ParkinWT
in the left side and elav-GAL4/CyO;UAS-ParkinLD in the right side. (M4V
4550 kb)
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